Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders

Ophthalmology

Volumn 121, Issue 3, 2014, Pages 785-796.e3

  Levy Clarke, Grace ^a   Jabs, Douglas A ^b,h   Read, Russell W ^c   Rosenbaum, James T ^d,e   Vitale, Albert ^f   Van Gelder, Russell N ^g  

^a St Luke's Cataract and Laser Institute   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e DEVERS EYE INSTITUTE   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BEHCET DISEASE; BIRDSHOT CHORIORETINITIS; CHORIORETINITIS; CHOROIDITIS; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; EVIDENCE BASED MEDICINE; EYE INFLAMMATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; META ANALYSIS (TOPIC); MULTIFOCAL CHOROIDITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RELAPSE; REMISSION; SARCOIDOSIS; SCLERITIS; SERONEGATIVE SPONDYLOARTHROPATHY; SPONDYLOARTHROPATHY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, JUVENILE; BEHCET SYNDROME; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; OPHTHALMOLOGY; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; SCLERITIS; SOCIETIES, MEDICAL; SPONDYLARTHROPATHIES; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UVEITIS;

EID: 84896724930     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.09.048     Document Type: Article

References (176)

1. D.A. Jabs, J.T. Rosenbaum, and C.S. Foster et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel Am J Ophthalmol 130 2000 492 513
2. P. Glasziou, J.P. Vandenbroucke, and I. Chalmers Assessing the quality of research BMJ 328 2004 39 41
3. H. Balshem, M. Helfand, and H.J. Schunemann et al. GRADE guidelines: 3. Rating the quality of evidence J Clin Epidemiol 64 2011 401 406
4. M. Keaney, and A.R. Lorimer Auditing the implementation of SIGN (Scottish Intercollegiate Guidelines Network) clinical guidelines Int J Health Care Qual Assur Inc Leadersh Health Serv 12 1999 314 317
5. L.L. Lim, F.W. Fraunfelder, and J.T. Rosenbaum Do tumor necrosis factor inhibitors cause uveitis? A registry-based study Arthritis Rheum 56 2007 3248 3252
6. J. Braun, X. Baraliakos, J. Listing, and J. Sieper Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept Arthritis Rheum 52 2005 2447 2451
7. E. Dommasch, and J.M. Gelfand Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 22 2009 418 430
8. J.H. Kempen, E. Daniel, and J.P. Dunn et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study BMJ 339 2009 b2480
9. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum 50 2004 1740 1751
10. E.F. Chakravarty, K. Michaud, and F. Wolfe Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors J Rheumatol 32 2005 2130 2135
11. F. Wolfe, and K. Michaud The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation Arthritis Rheum 56 2007 1433 1439
12. M.A. Lopez-Olivo, J.H. Tayar, and J.A. Martinez-Lopez et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis JAMA 308 2012 898 908
13. K.G. Saag, G.G. Teng, and N.M. Patkar et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 2008 762 784
14. M. Giganti, P.M. Beer, and N. Lemanski et al. Adverse events after intravitreal infliximab (Remicade) Retina 30 2010 71 80
15. International Study Group for Behçet's Disease Criteria for diagnosis of Behçet's disease Lancet 335 1990 1078 1080
16. A. Arida, K. Fragiadaki, E. Giavri, and P.P. Sfikakis Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients Semin Arthritis Rheum 41 2011 61 70
17. P.P. Sfikakis, N. Markomichelakis, and E. Alpsoy et al. Anti-TNF therapy in the management of Behçet's disease - review and basis for recommendations Rheumatology (Oxford) 46 2007 736 741
18. S. Ohno, S. Nakamura, and S. Hori et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis J Rheumatol 31 2004 1362 1368
19. E.W. Lindstedt, G.S. Baarsma, R.W. Kuijpers, and P.M. van Hagen Anti-TNF-alpha therapy for sight threatening uveitis Br J Ophthalmol 89 2005 533 536
20. M. Accorinti, M.P. Pirraglia, and M.P. Paroli et al. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease Jpn J Ophthalmol 51 2007 191 196
21. L. Niccoli, C. Nannini, and M. Benucci et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study Rheumatology (Oxford) 46 2007 1161 1164
22. S. Tognon, G. Graziani, and R. Marcolongo Anti-TNF-alpha therapy in seven patients with Behçet's uveitis: advantages and controversial aspects Ann N Y Acad Sci 1110 2007 474 484
23. I.K. Petropoulos, J.D. Vaudaux, and Y. Guex-Crosier Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital Klin Monbl Augenheilkd 225 2008 457 461
24. Y. Yamada, S. Sugita, and H. Tanaka et al. Timing of recurrent uveitis in patients with Behçet's disease receiving infliximab treatment Br J Ophthalmol 95 2011 205 208
25. Y. Yamada, S. Sugita, and H. Tanaka et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease Br J Ophthalmol 94 2010 284 288
26. K.F. Tabbara, and A.I. Al-Hemidan Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease Am J Ophthalmol 146 2008 845 850
27. N. Markomichelakis, E. Delicha, and S. Masselos et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet's disease: a comparative 4-week study Rheumatology (Oxford) 50 2011 593 597
28. A.A. Okada, H. Goto, S. Ohno, M. Mochizuki, and Ocular Behçet's Disease Research Group of Japan Multicenter study of infliximab for refractory uveoretinitis in Behçet disease Arch Ophthalmol 130 2012 592 598
29. J.A. van Laar, T. Missotten, and P.L. van Daele et al. Adalimumab: a new modality for Behçet's disease [letter]? Ann Rheum Dis 66 2007 565 566
30. K. Takase, S. Ohno, and H. Ideguchi et al. Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis Rheumatol Int 31 2011 243 245
31. B. Mushtaq, T. Saeed, R.D. Situnayake, and P.I. Murray Adalimumab for sight-threatening uveitis in Behçet's disease Eye (Lond) 21 2007 824 825
32. D. Perra, M.A. Alba, and J.L. Callejas et al. Adalimumab for the treatment of Behçet's disease: experience in 19 patients Rheumatology (Oxford) 51 2012 1825 1831
33. I. Olivieri, P. Leccese, and S. D'Angelo et al. Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab Clin Exp Rheumatol 29 suppl 2011 S54 S57
34. P. Leccese, L. Latanza, and S. D'Angelo et al. Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab [letter] Clin Exp Rheumatol 29 suppl 2011 S93
35. M. Melikoglu, I. Fresko, and C. Mat et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study J Rheumatol 32 2005 98 105
36. V. Curigliano, M. Giovinale, and C. Fonnesu et al. Efficacy of etanercept in the treatment of a patient with Behçet's disease Clin Rheumatol 27 2008 933 936
37. F. Atzeni, P. Sarzi-Puttini, and F. Capsoni et al. Successful treatment of resistant Behçet's disease with etanercept [letter] Clin Exp Rheumatol 23 2005 729
38. A. Sommer, P. Altmeyer, and A. Kreuter A case of mucocutaneous Behçet's disease responding to etanercept [letter] J Am Acad Dermatol 52 2005 717 719
39. C. Estrach, S. Mpofu, and R.J. Moots Behçet's syndrome: response to infliximab after failure of etanercept [letter] Rheumatology (Oxford) 41 2002 1213 1214
40. J.C. Richards, M.L. Tay-Kearney, K. Murray, and P. Manners Infliximab for juvenile idiopathic arthritis-associated uveitis Clin Experiment Ophthalmol 33 2005 461 468
41. R.T. Rajaraman, Y. Kimura, and S. Li et al. Retrospective case review of pediatric patients with uveitis treated with infliximab Ophthalmology 113 2006 308 314
42. P. Kahn, M. Weiss, L.F. Imundo, and D.M. Levy Favorable response to high-dose infliximab for refractory childhood uveitis Ophthalmology 113 2006 860 864
43. M. Gallagher, K. Quinones, and R.A. Cervantes-Castaneda et al. Biological response modifier therapy for refractory childhood uveitis Br J Ophthalmol 91 2007 1341 1344
44. G. Simonini, M.E. Zannin, and R. Caputo et al. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis Rheumatology (Oxford) 47 2008 1510 1514
45. S.P. Ardoin, D. Kredich, and E. Rabinovich et al. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up Am J Ophthalmol 144 2007 844 849
46. S. Biester, C. Deuter, and H. Michels et al. Adalimumab in the therapy of uveitis in childhood Br J Ophthalmol 91 2007 319 324
47. P. Tynjala, K. Kotaniemi, and P. Lindahl et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis Rheumatology (Oxford) 47 2008 339 344
48. L.B. Vazquez-Cobian, T. Flynn, and T.J. Lehman Adalimumab therapy for childhood uveitis J Pediatr 149 2006 572 575
49. M. Diaz-Llopis, D. Salom, and C. Garcia-de-Vicuna et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients Ophthalmology 119 2012 1575 1581
50. A. Reiff Long-term outcome of etanercept therapy in children with treatment-refractory uveitis [letter] Arthritis Rheum 48 2003 2079 2080
51. A. Reiff, S. Takei, and S. Sadeghi et al. Etanercept therapy in children with treatment-resistant uveitis Arthritis Rheum 44 2001 1411 1415
52. J.A. Smith, D.J. Thompson, and S.M. Whitcup et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis Arthritis Rheum 53 2005 18 23
53. C.S. Foster, F. Tufail, and N.K. Waheed et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate Arch Ophthalmol 121 2003 437 440
54. A. Galor, V.L. Perez, J.P. Hammel, and C.Y. Lowder Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation Ophthalmology 113 2006 2317 2323
55. R.K. Saurenmann, A.V. Levin, and B.M. Feldman et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents J Pediatr 149 2006 833 836
56. H. Schmeling, and G. Horneff Etanercept and uveitis in patients with juvenile idiopathic arthritis Rheumatology (Oxford) 44 2005 1008 1011
57. R.K. Saurenmann, A.V. Levin, and J.B. Rose et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis Rheumatology (Oxford) 45 2006 982 989
58. P. Tynjala, P. Lindahl, and V. Honkanen et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis Ann Rheum Dis 66 2007 548 550
59. I. Foeldvari, S. Nielsen, and J. Kummerle-Deschner et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey J Rheumatol 34 2007 1146 1150
60. G. Simonini, A. Taddio, and M. Cattalini et al. Prevention of flare recurrences in childhood refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab Arthritis Care Res (Hoboken) 63 2011 612 618
61. E.S. Sen, S. Sharma, and A. Hinchcliffe et al. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease-a case cohort interventional study Rheumatology (Oxford) 51 2012 2199 2203
62. Simonini G, Taddio A, Cattalini M, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J [serial online] 2013;11:16. Available at: http://www.ped-rheum.com/content/11/1/16. Accessed September 28, 2013.
63. A. Heiligenhaus, H. Michels, and C. Schumacher et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis Rheumatol Int 32 2012 1121 1133
64. M. Rudwaleit, E. Rodevand, and P. Holck et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study Ann Rheum Dis 68 2009 696 701
65. Y. El-Shabrawi, and J. Hermann Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis Ophthalmology 109 2002 2342 2346
66. M.D. Rossman, L.S. Newman, and R.P. Baughman et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis Sarcoidosis Vasc Diffuse Lung Dis 23 2006 201 208
67. B.A. Cruz, D.D. Reis, C.A. Araujo Minas Gerais Vasculitis Study Group Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab Rheumatol Int 27 2007 1181 1183
68. R.P. Baughman, D.A. Bradley, and E.E. Lower Infliximab in chronic ocular inflammation Int J Clin Pharmacol Ther 43 2005 7 11
69. J.D. Doty, J.E. Mazur, and M.A. Judson Treatment of sarcoidosis with infliximab Chest 127 2005 1064 1071
70. R.P. Baughman, E.E. Lower, and D.A. Bradley et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial Chest 128 2005 1062-47
71. J. Suzuki, and H. Goto Uveitis associated with sarcoidosis exacerbated by etanercept therapy [letter] Jpn J Ophthalmol 53 2009 439 440
72. P.J. Hashkes, and I. Shajrawi Sarcoid-related uveitis occurring during etanercept therapy Clin Exp Rheumatol 21 2003 645 646
73. M. Samimi, G. Lorette, and L. Machet et al. Facial granulomatous nodules during etanercept treatment for psoriasis [letter] Int J Dermatol 48 2009 1025 1027
74. E. Toussirot, E. Pertuiset, B. Kantelip, and D. Wendling Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases Clin Exp Rheumatol 26 2008 471 475
75. A. Kudrin, E.R. Chilvers, and A. Ginawi et al. Sarcoid-like granulomatous disease following etanercept treatment for RA [letter] J Rheumatol 34 2007 648 649
76. M.A. Gonzalez-Lopez, R. Blanco, and M.C. Gonzalez-Vela et al. Development of sarcoidosis during etanercept therapy Arthritis Rheum 55 2006 817 820
77. S.J. Ahn, J.Y. Oh, M.K. Kim, and W.R. Wee Treating refractory scleritis with infliximab [letter] Jpn J Ophthalmol 53 2009 286 287
78. N. Huynh, R.A. Cervantes-Castaneda, and P. Bhat et al. Biologic response modifier therapy for psoriatic ocular inflammatory disease Ocul Immunol Inflamm 16 2008 89 93
79. C. Prendiville, M. O'Doherty, P. Moriarty, and L. Cassidy The use of infliximab in ocular inflammation Br J Ophthalmol 92 2008 823 825
80. S. Cazabon, K. Over, and J. Butcher The successful use of infliximab in resistant relapsing polychondritis and associated scleritis [letter] Eye (Lond) 19 2005 222 224
81. C.C. Murphy, W.H. Ayliffe, and A. Booth et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis Ophthalmology 111 2004 352 356
82. H.N. Sen, A. Sangave, and K. Hammel et al. Infliximab for the treatment of active scleritis [report online] Can J Ophthalmol 44 2009 e9 12
83. M. Kontkanen, L. Paimela, and K. Kaarniranta Regression of necrotizing scleritis in Wegener's granulomatosis after infliximab treatment [letter][report online] Acta Ophthalmol 88 2010 e96 e97
84. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis N Engl J Med 352 2005 351 361
85. J.H. Stone, P.A. Merkel, and R. Spiera RAVE-ITN Research Group Rituximab versus cyclophosphamide for ANCA-associated vasculitis N Engl J Med 363 2010 221 232
86. E.B. Suhler, J.R. Smith, and T.R. Giles et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial [letter] Arch Ophthalmol 127 2009 819 822
87. E.B. Suhler, J.R. Smith, and M.S. Wertheim et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes Arch Ophthalmol 123 2005 903 912
88. P. Artornsombudh, O. Gevorgyan, and A. Payal et al. Infliximab treatment of patients with birdshot retinochoroidopathy Ophthalmology 120 2013 588 592
89. Y. Wang, and P.A. Gaudio Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome Ocul Immunol Inflamm 16 2008 167 171
90. Y.M. Khalifa, M.R. Bailony, and N.R. Acharya Treatment of pediatric Vogt-Koyanagi-Harada syndrome with infliximab Ocul Immunol Inflamm 18 2010 218 222
91. L. Niccoli, C. Nannini, and E. Cassara et al. Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease [letter] Br J Ophthalmol 93 2009 1553 1554
92. J.M. Benitez-del-Castillo, J.M. Martinez-de-la-Casa, and E. Pato-Cour et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab) Eye (Lond) 19 2005 841 845
93. P. Seve, E. Mennesson, and J.D. Grange et al. Infliximab in serpiginous choroiditis [letter][report online] Acta Ophthalmol 88 2010 e342 e343
94. E.B. Suhler, C.Y. Lowder, and D.A. Goldstein et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial Br J Ophthalmol 97 2013 481 486
95. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med [serial online] 2009;6(7):e1000097. Available at: http://www.plosmedicine.org/ article/info%3Adoi%2F10.1371%2Fjournal.pmed.1000097. Accessed September 28, 2013.
96. R. Horai, and R.R. Caspi Cytokines in autoimmune uveitis J Interferon Cytokine Res 31 2011 733 744
97. A.G. Commodaro, V. Bueno, R. Belfort Jr., and L.V. Rizzo Autoimmune uveitis: the associated proinflammatory molecules and the search for immunoregulation Autoimmun Rev 10 2011 205 209
98. R. Caspi Autoimmunity in the immune privileged eye: pathogenic and regulatory T cells Immunol Res 42 2008 41 50
99. A. Amadi-Obi, C.R. Yu, and X. Liu et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1 Nat Med 13 2007 711 718
100. K.M. Mohler, D.S. Torrance, and C.A. Smith et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists J Immunol 151 1993 1548 1561
101. P.H. Wooley, J. Dutcher, M.B. Widmer, and S. Gillis Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice J Immunol 151 1993 6602 6607
102. J.J. Hooks, C.C. Chan, and B. Detrick Identification of the lymphokines, interferon-gamma and interleukin-2, in inflammatory eye diseases Invest Ophthalmol Vis Sci 29 1988 1444 1451
103. J.A. van Laar, and P.M. van Hagen Cytokines in uveitis Clin Med Res 4 2006 248 249
104. B.J. Scallon, M.A. Moore, and H. Trinh et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
105. H.M. van Dullemen, S.J. van Deventer, and D.W. Hommes et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 1995 129 135
106. P.I. Murray, R. Hoekzema, and M.A. van Haren et al. Aqueous humor interleukin-6 levels in uveitis Invest Ophthalmol Vis Sci 31 1990 917 920
107. W.A. Franks, G.A. Limb, and M.R. Stanford et al. Cytokines in human intraocular inflammation Curr Eye Res 11 Suppl 1992 187 191
108. G.N. Palexas, G. Sussman, and N.H. Welsh Ocular and systemic determination of IL-1 beta and tumour necrosis factor in a patient with ocular inflammation Scand J Immunol Suppl 11 1992 173 175
109. R.R. Caspi Experimental autoimmune uveoretinitis in the rat and mouse Curr Protoc Immunol 2003 Chapter 15: Unit 15.6
110. A.D. Dick, P.G. McMenamin, and H. Korner et al. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina Eur J Immunol 26 1996 1018 1025
111. S. Nakamura, T. Yamakawa, and M. Sugita et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice Invest Ophthalmol Vis Sci 35 1994 3884 3889
112. M. Robertson, J. Liversidge, J.V. Forrester, and A.D. Dick Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis Invest Ophthalmol Vis Sci 44 2003 3034 3041
113. L.V. Rizzo, H. Xu, and C.C. Chan et al. IL-10 has a protective role in experimental autoimmune uveoretinitis Int Immunol 10 1998 807 814
114. T.K. Tarrant, P.B. Silver, and C.C. Chan et al. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis J Immunol 161 1998 122 127
115. R.R. Caspi, B. Sun, and R.K. Agarwal et al. T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile Eye (Lond) 11 Pt 2 1997 209 212
116. M. Busch, D. Bauer, and M. Hennig et al. Effects of systemic and intravitreal TNF-alpha inhibition in experimental autoimmune uveoretinitis Invest Ophthalmol Vis Sci 54 2013 39 46
117. L.S. Jones, L.V. Rizzo, and R.K. Agarwal et al. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response J Immunol 158 1997 5997 6005
118. J.T. Rosenbaum, P. Kievit, and Y.B. Han et al. Interleukin-6 does not mediate endotoxin-induced uveitis in mice: studies in gene deletion animals Invest Ophthalmol Vis Sci 39 1998 64 69
119. J.T. Rosenbaum, Y.B. Han, and J.M. Park et al. Tumor necrosis factor-alpha is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice J Rheumatol 25 1998 2408 2416
120. A.E. Goldfeld, and E.Y. Tsai TNF-alpha and genetic susceptibility to parasitic disease Exp Parasitol 84 1996 300 303
121. A.M. Reimold TNFalpha as therapeutic target: new drugs, more applications Curr Drug Targets Inflamm Allergy 1 2002 377 392
122. Y.J. Cheng, B.C. Yang, and W.C. Hsieh et al. Enhancement of TNF-alpha expression does not trigger apoptosis upon exposure of glial cells to lead and lipopolysaccharide Toxicology 178 2002 183 191
123. A.F. Kavanaugh Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis Rheum Dis Clin North Am 24 1998 593 614
124. G.G. Illei, and P.E. Lipsky Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases Curr Opin Immunol 12 2000 712 718
125. H. Zhou Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein J Clin Pharmacol 45 2005 490 497
126. E.C. Keystone Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis Rheum Dis Clin North Am 27 2001 427 443
127. V. Thyagarajan, H. Norman, and K.A. Alexander et al. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients Semin Arthritis Rheum 42 2012 223 233
128. J. Gan, A.M. Manadan, W. Sequiera, and J.A. Block Tuberculosis infections and tumor necrosis factor alpha antagonists Am J Ther 20 2013 73 78
129. F. Tubach, D. Salmon, and P. Ravaud et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry Arthritis Rheum 60 2009 1884 1894
130. A. Fonollosa, A. Segura, J. Giralt, and J. Garcia-Arumi Tuberculous uveitis after treatment with etanercept Graefes Arch Clin Exp Ophthalmol 245 2007 1397 1399
131. P. Lozeron, C. Denier, C. Lacroix, and D. Adams Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy Arch Neurol 66 2009 490 497
132. M. Louis, J. Rauch, M. Armstrong, and M.A. Fitzcharles Induction of autoantibodies during prolonged treatment with infliximab J Rheumatol 30 2003 2557 2562
133. P. Caramaschi, L.M. Bambara, and S. Pieropan et al. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases Joint Bone Spine 76 2009 333 342
134. E. Laffitte, J.P. Janssens, and P. Roux-Lombard et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test Br J Dermatol 161 2009 797 800
135. V.S. Theis, and J.M. Rhodes Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease Aliment Pharmacol Ther 27 2008 19 30
136. F. Beigel, F. Schnitzler, and R. Paul Laubender et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease Inflamm Bowel Dis 17 2011 91 98
137. E.B. Suhler, J.R. Smith, and T.R. Giles et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial Arch Ophthalmol 127 2009 819 822
138. L.L. Lim, F.W. Fraunfelder, and J.T. Rosenbaum Do tumor necrosis factor inhibitors cause uveitis? A registry-based study Arthritis Rheum 56 2007 3248 3252
139. J. Sieper Developments in the scientific and clinical understanding of the spondyloarthritides Arthritis Res Ther 11 2009 208
140. R. Scrivo, A. Spadaro, F.R. Spinelli, and G. Valesini Uveitis following the use of tumor necrosis factor alpha inhibitors: comment on the article by Lim et al Arthritis Rheum 58 2008 1555 1556 author reply 6-7
141. P.P. Sfikakis, and N. Markomichelakis Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al Arthritis Rheum 58 2008 1554 1555 author reply 6-7
142. B.J. Sheane, D. Howard, M.F. Doran, and G. Cunnane Link between tumor necrosis factor inhibitors and onset of uveitis: comment on the article by Lim et al Arthritis Rheum 58 2008 1554 author reply 6-7
143. R.K. Saurenmann, A.V. Levin, and B.M. Feldman et al. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFalpha agents J Pediatr 149 2006 833 836
144. D. Fouache, V. Goeb, and N. Massy-Guillemant et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study Rheumatology (Oxford) 48 2009 761 764
145. A. Bouchra, K. Benbouazza, and N. Hajjaj-Hassouni Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy Clin Rheumatol 28 Suppl 1 2009 S53 S55
146. P.J. Hashkes, and I. Shajrawi Sarcoid-related uveitis occurring during etanercept therapy Clin Exp Rheumatol 21 2003 645 646
147. P.P. Sfikakis, A. Iliopoulos, and A. Elezoglou et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction Arthritis Rheum 52 2005 2513 2518
148. L. Garrison, and N.D. McDonnell Etanercept: therapeutic use in patients with rheumatoid arthritis Ann Rheum Dis 58 Suppl 1 1999 I65 59
149. S.J. Bickston, G.R. Lichtenstein, and K.O. Arseneau et al. The relationship between infliximab treatment and lymphoma in Crohn's disease Gastroenterology 117 1999 1433 1437
150. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum 50 2004 1740 1751
151. C. Bucher, L. Degen, and S. Dirnhofer et al. Biologics in inflammatory disease: infliximab associated risk of lymphoma development Gut 54 2005 732 733
152. D.C. Burger, and T.H. Florin Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease Med J Aust 190 2009 341 342
153. E. Dommasch, and J.M. Gelfand Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 22 2009 418 430
154. X. Mariette, F. Tubach, and H. Bagheri et al. Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry Ann Rheum Dis 69 2010 400 408
155. L. Mellemkjaer, M.S. Linet, and G. Gridley et al. Rheumatoid arthritis and cancer risk Eur J Cancer 32A 1996 1753 1757
156. E. Baecklund, A. Ekbom, and P. Sparen et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study BMJ 317 1998 180 181
157. J.H. Kempen, S. Gangaputra, and E. Daniel et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence Am J Ophthalmol 146 2008 802-12 e1
158. P. Diak, J. Siegel, and L. La Grenade et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration Arthritis Rheum 62 2010 2517 2524
159. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement Am J Respir Crit Care Med 161 2000 S221 S247
160. H. Hosseini, A. Safaei, and M.R. Khalili et al. Intravitreal infliximab in experimental endotoxin-induced uveitis Eur J Ophthalmol 19 2009 818 823
161. P.G. Theodossiadis, V.S. Liarakos, and P.P. Sfikakis et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit Graefes Arch Clin Exp Ophthalmol 247 2009 273 281
162. F. Giansanti, M. Ramazzotti, and L. Vannozzi et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model Invest Ophthalmol Vis Sci 49 2008 1151 1156
163. M. Farvardin, M. Afarid, M. Mehryar, and H. Hosseini Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis Retina 30 2010 1530 1535
164. M. Farvardin, M. Afarid, and S. Shahrzad Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis J Ocul Pharmacol Ther 28 2012 628 631
165. L. Wu, J.F. Arevalo, and E. Hernandez-Bogantes et al. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group J Ocul Pharmacol Ther 29 2013 366 371
166. L. Arias, J.M. Caminal, and M.B. Badia et al. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy Retina 30 2010 1601 1608
167. L. Wu, J.F. Arevalo, E. Hernandez-Bogantes, and J.A. Roca Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group Int Ophthalmol 32 2012 235 243
168. L. Wu, E. Hernandez-Bogantes, and J.A. Roca et al. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group Retina 31 2011 298 303
169. J.S. Pulido, J.E. Pulido, C.J. Michet, and R.G. Vile More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial Retina 30 2010 1 5
170. F. Woreta, J.E. Thorne, and D.A. Jabs et al. Risk factors for ocular complications and poor visual acuity at presentation among patients with uveitis associated with juvenile idiopathic arthritis Am J Ophthalmol 143 2007 647 655
171. J.E. Thorne, F. Woreta, and S.R. Kedhar et al. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss Am J Ophthalmol 143 2007 840 846
172. L.I. Kump, R.A. Castaneda, and S.N. Androudi et al. Visual outcomes in children with juvenile idiopathic arthritis-associated uveitis Ophthalmology 113 2006 1874 1877
173. J.C. Richards, M.L. Tay-Kearney, K. Murray, and P. Manners Infliximab for juvenile idiopathic arthritis-associated uveitis Clin Experiment Ophthalmol 33 2005 461 468
174. L.S. Tam, J. Gu, and D. Yu Pathogenesis of ankylosing spondylitis Nat Rev Rheumatol 6 2010 399 405
175. J. Braun, X. Baraliakos, J. Listing, and J. Sieper Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept Arthritis Rheum 52
176. D.A. Jabs, and C.J. Johns Ocular involvement in chronic sarcoidosis Am J Ophthalmol 102 1986 297 301